Synonym
DM-4107; DM4107; DM 4107;
IUPAC/Chemical Name
4-(5-chloro-2-(2-methyl-4-(2-methylbenzamido)benzamido)phenyl)-4-hydroxybutanoic acid
InChi Key
AJMZAIPORREFDJ-UHFFFAOYSA-N
InChi Code
1S/C26H25ClN2O5/c1-15-5-3-4-6-19(15)25(33)28-18-8-9-20(16(2)13-18)26(34)29-22-10-7-17(27)14-21(22)23(30)11-12-24(31)32/h3-10,13-14,23,30H,11-12H2,1-2H3,(H,28,33)(H,29,34)(H,31,32)
SMILES Code
CC1=CC=CC=C1C(=O)NC2=CC=C(C(=O)NC3=CC=C(Cl)C=C3C(O)CCC(O)=O)C(C)=C2
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
480.95
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ma Y, Yu M, Wang H. Development, validation and application of a UPLC-MS/MS method for simultaneous quantification of OPC-61815 and its metabolites tolvaptan, DM-4103 and DM-4107 in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Jul 15;1242:124213. doi: 10.1016/j.jchromb.2024.124213. Epub 2024 Jun 19. PMID: 38909567.
2: Hammond S, Gibson A, Jaruthamsophon K, Roth S, Mosedale M, Naisbitt DJ. Shedding Light on Drug-Induced Liver Injury: Activation of T Cells From Drug Naive Human Donors With Tolvaptan and a Hydroxybutyric Acid Metabolite. Toxicol Sci. 2021 Jan 6;179(1):95-107. doi: 10.1093/toxsci/kfaa157. PMID: 33078835.
3: Lu Y, Slizgi JR, Brouwer KR, Claire RL, Freeman KM, Pan M, Brock WJ, Brouwer KL. Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes. Drug Metab Dispos. 2016 Jun;44(6):867–70. doi: 10.1124/dmd.115.067629. Epub 2016 Mar 24. PMID: 27013400; PMCID: PMC4885486.
4: Beaudoin JJ, Bezençon J, Cao Y, Mizuno K, Roth SE, Brock WJ, Brouwer KLR. Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease. Drug Metab Dispos. 2019 Feb;47(2):155-163. doi: 10.1124/dmd.118.083907. Epub 2018 Nov 30. Erratum in: Drug Metab Dispos. 2019 Mar;47(3):328. doi: 10.1124/dmd.115.083907err. PMID: 30504136; PMCID: PMC6338823.
5: Liu H, Wang Y, Liu T, Chen Y, Zheng X, Liu M, Zhao Q, Zeng M, Jiang J, Mao Y, Hu P. Pharmacokinetics, pharmacodynamics and safety of 15 mg-tolvaptan administered orally for 7 consecutive days to Chinese patients with child-Pugh B cirrhosis. Front Pharmacol. 2024 Jan 26;15:1324299. doi: 10.3389/fphar.2024.1324299. PMID: 38344178; PMCID: PMC10853469.
6: Slizgi JR, Lu Y, Brouwer KR, St Claire RL, Freeman KM, Pan M, Brock WJ, Brouwer KL. Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury? Toxicol Sci. 2016 Jan;149(1):237-50. doi: 10.1093/toxsci/kfv231. Epub 2015 Oct 26. PMID: 26507107; PMCID: PMC6169477.
7: Jiang J, Tian L, Huang Y, Yan Y, Li Y. A rapid and sensitive LC-MS/MS-ESI method for the determination of tolvaptan and its two main metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Aug 1;1027:158-64. doi: 10.1016/j.jchromb.2016.03.032. Epub 2016 May 6. PMID: 27288933.
